Q-omics provides the consensus-scored NXPH2 profile across patient tissues and cancer cell-line models. NXPH2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, NXPH2 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, NXPH2 RNA expression shows 13,992 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight ACC, KIRC, and TGCT as cancer lineages where NXPH2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NXPH2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NXPH2 survival associations across molecular data types. NXPH2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NXPH2 RNA expression–survival associations across cancer types. High NXPH2 expression shows unfavorable associations in ACC, STAD, UVM and UCEC, but favorable associations in BRCA and UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for NXPH2 RNA expression.
This table summarizes NXPH2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NXPH2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NXPH2 shows lower tumor expression in KIRC, KIRP, STAD, COAD, READ and UCEC. The KIRC box plot shows higher NXPH2 RNA expression in normal versus tumor tissue (log2 FC = −2.120, t-test p < 0.001).
This table shows molecular features associated with NXPH2 in patient tissues and cancer cell lines. In patient samples, NXPH2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, NXPH2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BONE.
